v3.26.1
Condensed Consolidated Statements of Assets and Liabilities - USD ($)
Jun. 30, 2026
Dec. 31, 2025
ASSETS    
Investments at fair value $ 13,364,295,000 $ 14,207,294,000
Cash and Cash Equivalent 267,155,000 289,605,000
Receivable from broker 1,837,000 11,286,000
Deferred financing costs 19,774,000 19,753,000
Receivable for investments 25,180,000 3,187,000
Derivative assets at fair value (Note 6) 2,462,000 19,633,000
Total assets 13,788,668,000 14,656,463,000
LIABILITIES    
Debt (net of unamortized debt issuance costs of $51,435 and $39,900, respectively) 7,536,067,000 8,080,129,000
Payable for investments 9,642,000 2,172,000
Management fees payable (Note 3) 35,282,000 36,141,000
Income based incentive fees payable (Note 3) 1,690,000 26,400,000
Capital gains based incentive fees payable (Note 3) 0 0
Interest payable 62,772,000 61,952,000
Derivative liabilities at fair value (Note 6) 6,002,000 0
Distribution payable 179,142,000 178,616,000
Board of Trustees’ fees payable 311,000 289,000
Accrued expenses and other liabilities 13,664,000 20,772,000
Total liabilities 7,849,935,000 8,411,288,000
Commitments and contingencies (Note 8)
NET ASSETS    
Common Shares, $0.001 par value (unlimited shares authorized; 232,652,003 and 231,969,058 shares issued and outstanding, respectively) 233,000 232,000
Additional paid in capital 6,064,572,000 6,047,750,000
Distributable earnings (loss) (126,072,000) 197,193,000
Total net assets 5,938,733,000 6,245,175,000
Total liabilities and net assets $ 13,788,668,000 $ 14,656,463,000
NET ASSET VALUE PER SHARE (in usd per share) $ 25.53 $ 26.92
Affiliated Entity    
LIABILITIES    
Due to affiliates $ 5,363,000 $ 4,817,000
Non-controlled/non-affiliated investments    
ASSETS    
Investments at fair value 13,221,914,000 [1],[2] 14,167,499,000 [3],[4]
Interest receivable from non-controlled/non-affiliated investments 107,926,000 105,695,000
Non-controlled/affiliated investments    
ASSETS    
Investments at fair value 142,381,000 [1],[2] 39,795,000 [3],[4]
Interest receivable from non-controlled/non-affiliated investments $ 39,000 $ 10,000
[1] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) and may be deemed to be “restricted securities.” As of June 30, 2026, the aggregate fair value of these securities is $13,364.3 million or 225.04% of the Company’s net assets. The initial acquisition dates have been included for such securities.
[2] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in U.S. dollars. As of June 30, 2026, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.
[3] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), excluding Axsome Therapeutics, Inc. - Common Stock, and may be deemed to be “restricted securities.” As of December 31, 2025, the aggregate fair value of these securities is $14,206.9 million or 227.48% of the Company’s net assets. The initial acquisition dates have been included for such securities.
[4] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in U.S. dollars. As of December 31, 2025, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.